Active clinical trials for "Prostatic Neoplasms"

The purpose of this study is to determine which technique in using a vacuum erection device (VED) is best. Erectile dysfunction (ED) after robotic prostate cancer surgery is a concern for both the surgeon and the patient. Recent studies have shown that beginning to use the vacuum pump on a daily basis starting with in 2-8 weeks may help prevent the start of penile shrinkage. This is a potential issue that can occur because of decreased blood flow after prostate cancer surgery. This study will allow researchers to determine and compare vacuum therapy techniques and erectile function outcomes of patients who have prostate cancer surgery

The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer (PCa). Set the prognosis at baseline. Evaluate the response to different treatments (predictive value and monitoring). Establish individualized therapies.

Social comparisons may function as a coping strategy, but their role in coping and quality of life has not been well characterized. The purpose of the current study is to investigate the relationships between cognitive appraisals; coping strategies; social comparisons; and quality of life among men with prostate cancer. The conceptual framework for this study is drawn from Festinger s Social Comparison Theory, Lazarus and Folkman s Transactional Model of Stress and Coping, and Mishel s Uncertainty in Illness Theory. A cancer diagnosis is accompanied by uncertainty about how cancer will affect one s life. Theory and empirical data suggest that in conditions of uncertainty, coping affects adjustment to a condition. Social comparisons have been postulated to be more prevalent in uncertain situations. Because little is known about how social comparisons operate, participants in this study will be recruited exclusively from prostate cancer support groups. Support groups provide a context in which individuals are likely to make social comparisons and to be cognizant of these comparisons. Prostate cancer provides a model of a common, chronic condition with complex etiology. Prostate cancer treatment may cause sexual, urinary, and bowel side effects, which may affect patients quality of life and elicit attempts to cope. One way of managing the prostate cancer experience may be to compare oneself to others who are doing better or worse than oneself on relevant dimensions. The interpretation of social comparisons may positively or negatively affect one s perceived quality of life. There have been no studies among prostate cancer patients that have quantitatively measured the use of social comparisons. There is also a paucity of research in this population regarding the predictors of coping strategies and the predictors of quality of life across multiple domains. This study will use a cross-sectional, mixed methods survey to investigate relationships between cognitive appraisals, coping, and quality of life and to qualitatively explore social comparisons among men with prostate cancer. Participants may complete the survey on paper or online. The primary outcomes are the use of coping strategies, including social comparisons, and quality of life. Individuals with a personal or family history of prostate cancer are currently seen by genetic counselors as part of research studies investigating the genetic basis of prostate cancer. If relationships are demonstrated between the social comparisons and quality of life, genetic counselors may want to assess patients social comparisons to evaluate how patients are coping with their condition.

Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.

The REDUCE trial was conducted to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Dutasteride was compared with placebo for 4 years period. Results showed a relative risk reduction of 22.8 % (95% CI: 15.2 to 29.8)in prostate cancer. For REDUCE, biopsies were defined as "protocol biopsy" if performed at certain timeframes, and "for cause" if outside these predetermined timeframes. The investigators propose a post hoc analysis that would allow them to include biopsies that really justified a clinical indication, but were excluded from "for cause" analysis based on occurring at either the 2 or 4 year timeframes. Thus the investigators propose analysis of both REDUCE groups by every yearly timeframe as: Group 1--dutasteride group biopsied "for cause" using several definitions: biopsy of patients who received dutasteride whose PSA rose from nadir as defined in your own protocol,who had a PSA rise>0.2 ng/ml or who had a new abnormal DRE or had a free PSA<12% . The investigators define these as such because this would reasonably instigate biopsy if the clinician had a patient with this scenario in the non-study setting. Group 2--placebo group biopsied "for cause" using several definitions, regardless of timeframe but reported at each year of the study and aggregate, with the aggregate number being the primary outcome. Thus the investigators would request results of biopsy of patients who received placebo To establish differences in biopsy positive rates the groups as per each definition listed, to determine if dutasteride decreased the likelihood of "for cause" biopsy compared to "not for cause" biopsy, and if there is a difference in cancer detection risk rate depending on cause vs. no cause in that group compared to placebo.

The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.

Open study to make a comparison between hypogonadism and euogonadism patients regarding the severity of prostate cancer. The purpose of this study is to determine the importance of the relationship between the hormonal status and the type of the tumor at the time of surgical intervention as well as follow up of the patients.

This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.

The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer participants in daily medical practice.

Radiotherapy is the commonest form of prostate cancer treatment in the UK. In one in four men, radiotherapy will fail to control the cancer. These men are offered hormonal treatment which has significant side effects. Few men are offered a further treatment such as surgery, HIFU or cryotherapy. Only half of these men are cancer free at 5 years. The investigators believe this is due to poor imaging tests such as CT and Bone scan that cannot accurately detect whether cancer has come back inside or outside of the prostate or both. Also radiotherapy damages tissue surrounding the prostate which affects tissue healing for example after surgery. Treating just the cancer in the prostate only (focal treatment) rather than the whole prostate may limit this damage and cause fewer side-effects. The investigators want to see if new imaging tests can better identify cancer that has spread outside of the prostate and areas of cancer inside the prostate. Our new tests are whole-body MRI (for distant disease) and MRI guided biopsies (MRI-TB) (for local disease). First, the investigators will compare the results of whole-body MRI to existing imaging tests (bone-scan, and choline PET/CT) that try to find distant spread. Second, the investigators will compare the results of MRI-TB to a very detailed and accurate biopsy of the prostate called template prostate mapping which will show us where and how aggressive the cancer is. Third, if the cancer is confined to the prostate, the investigators will treat men using focal salvage therapies HIFU and cryotherapy. The investigators believe that these new imaging tests could better identify those who will benefit from early hormone treatment and those who will benefit from local salvage treatment. Our study may help justify carrying out a larger trial looking at how good the treatment is in controlling cancer in the medium and long-term.